Biological
Arepanrix®
Arepanrix® is a biological therapy with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Phase Distribution
Ph phase_4
3
75%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 4Post-market surveillance
3(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 43 (100.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_4
Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older
NCT01114620
completedphase_4
Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV
NCT01002040
completedphase_4
Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults
NCT01001026
completed
Drug Use Investigation for Arepanrix® (H1N1)
NCT02069496
Clinical Trials (4)
Showing 4 of 4 trials
NCT01114620Phase 4
Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older
NCT01002040Phase 4
Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV
NCT01001026Phase 4
Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults
NCT02069496
Drug Use Investigation for Arepanrix® (H1N1)
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4